PRELUDE THERAPEUTICS INC
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | $-99.5M | $-127.2M | $-121.8M | $-115.4M | $-111.7M | $-56.9M | $-27.6M |
| Depreciation & Amortization | $1.7M | $1.8M | $1.2M | $1.3M | $915.0K | $542.0K | $382.0K |
| Depreciation | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — |
| Stock-Based Compensation | $11.9M | $21.3M | $25.6M | $25.1M | $20.9M | $5.6M | $846.0K |
| Net Cash from Operating Activities | $-56.3M | $-102.9M | $-107.1M | $-83.7M | $-83.5M | $-46.2M | $-25.7M |
| Investing Activities | |||||||
| Capital Expenditures | $67.0K | $764.0K | $3.5M | $3.0M | $2.3M | $621.0K | $780.0K |
| Business Acquisitions | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $53.5M | $90.2M | $-34.6M | $81.7M | $-263.8M | $-621.0K | $-780.0K |
| Financing Activities | |||||||
| Dividends Paid | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $24.8M | $-120.0K | $136.4M | $815.0K | $164.9M | $246.2M | $29.7M |
| Net Change in Cash | $22.0M | $-12.8M | $-5.3M | $-1.2M | $-182.4M | $199.4M | $3.3M |
| Free Cash Flow | $-56.4M | $-103.7M | $-110.6M | $-86.7M | $-85.9M | $-46.8M | $-26.4M |